| Phase 13 trials |
|
Phase 1
|
NCT05193604 |
Mar 2022 → Nov 2023 |
— |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Terminated
|
No outcome recorded
Stop: Business |
|
Phase 1
|
NCT05068921 |
Dec 2021 → May 2023 |
cervical cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT04805060 |
Apr → Dec 2021 |
cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT05154630 |
Jan 2022 → Mar 2023 |
cancer of unknown primary site, soft tissue sarcoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT05198531 |
Jan → Oct 2022 |
nasopharyngeal carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT05262101 |
May 2022 → Jun 2023 |
sarcoma |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT05121363 |
Dec 2021 → May 2023 |
endometrial carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|